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ABSTRACT 
 
 Energy-dependent transporters of the ATP-binding cassette (ABC) family regulate the 
movement of molecules across cellular membranes. Several of these transporters are 
expressed in the endothelial cells of brain microvessels (blood-brain barrier) to protect brain 
tissue from exposure to toxins in the blood. Three of the most common ABC transporters at 
the blood-brain barrier are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), 
and multidrug resistance protein 1 (MRP1). Changes in P-gp function and density are 
hypothesized to play a role in neurological disorders, mediating drug-resistant epilepsy, drug 
effectiveness against HIV infection of the brain, and Alzheimer disease. Therefore, to 
measure P-gp function and density in vivo, substrates (which are transported by P-gp) and 
inhibitors (which bind to P-gp) have been radiolabeled for use in the nuclear imaging 
technique positron emission tomography (PET). For accurate quantification, radiotracers 
must be selective for P-gp and have high signal strength. The purpose of this thesis was to 
evaluate whether two radiotracers that are used to image P-gp function and density fulfill 
these properties. 
The selectivity and signal strength of the P-gp substrate N-desmethyl-loperamide (dLop) 
and the P-gp inhibitor tariquidar were assessed using pharmacology assays in human cell 
lines and post-mortem mouse brains, and using PET imaging in transgenic mice and healthy 
humans. We found that the radiotracer [11C]dLop is selective as a substrate for P-gp among 
the three major ABC transporters of the blood-brain barrier because accumulation of 
[3H]dLop was lowest in cells expressing P-gp, and the uptake of [11C]dLop was highest in 
brains of mice lacking P-gp. In addition to being selective, dLop is ionically trapped in acidic 
lysosomes; [3H]dLop accumulation decreased by ≥ 50% in human cells pretreated with 
compounds that raise lysosomal pH. This irreversible trapping mechanism of [11C]dLop 
amplifies the measured PET signal because radioactivity accumulates over time. However, 
the P-gp inhibitor tariquidar competes with dLop for lysosomal accumulation because it 
decreased the accumulation of [3H]dLop by ≥ 50% in human cells and that of [11C]dLop by ≥ 
35-40% in lysosome-rich organs of P-gp knockout mice and healthy humans; competition 
was not observed in the brain. The lysosomal competition in the peripheral organs is 
problematic because tariquidar is used in combination with [11C]dLop to measure P-gp 
function in vivo and suggests that these two compounds cannot be used together to measure 
P-gp function in the periphery. 
We also found that tariquidar is not a specific inhibitor of P-gp; it is also a substrate and 
inhibitor of BCRP. At low concentrations, [3H]tariquidar had highest accumulation in cells 
expressing P-gp and lowest accumulation in cells expressing BCRP, while at higher 
concentrations (≥ 100 nM), tariquidar inhibited the function of both P-gp and BCRP. In 
addition to not being selective, [11C]tariquidar has a low signal strength as a radiotracer 
because specific binding of [3H]tariquidar to P-gp in post-mortem mouse brains was only 20-
30% of the total signal. 
In conclusion, the selectivity and high signal strength of the radiotracer [11C]dLop allow 
it to selectively measure P-gp function at the blood-brain barrier and this radiotracer can be 
used to determine P-gp’s role in neurological disorders. In contrast, the lack of selectivity 
and low signal strength of [11C]tariquidar indicate that this inhibitor cannot measure P-gp 
density and that better inhibitor radiotracers are required. 
 
 
 
 
